Profile data is unavailable for this security.
About the company
Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the development, manufacturing & sale of pharmaceutical products and services& trading of commodities and renting of properties. The Company manufactures and markets more than 200 pharmaceutical formulation products in various dosage forms, like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections and Dry Vial injections, Dry Syrups, Ointments and Inhalers. The Company's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Albendazole Oral Suspension USP 100mg, Cetirizine Oral Solution BP, Clotrimazole Cream USP, Compound Benzoic Acid Ointment BP, and others.
- Revenue in INR (TTM)5.03bn
- Net income in INR689.58m
- Incorporated1988
- Employees554.00
- LocationSyncom Formulations (India) Ltd207, Saket NagarINDORE 452018IndiaIND
- Phone+91 7 312700458
- Fax+91 7 313046872
- Websitehttps://syncomformulations.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anuh Pharma Ltd | 7.68bn | 418.22m | 7.78bn | 295.00 | 18.59 | -- | 14.69 | 1.01 | 4.17 | 4.17 | 76.65 | -- | -- | -- | -- | 26,023,040.00 | -- | 10.41 | -- | 17.00 | 22.25 | 23.95 | 5.45 | 7.35 | -- | 116.27 | -- | 26.59 | 2.24 | 16.60 | -21.16 | 27.05 | -10.78 | 16.89 |
| Accent Microcell Ltd | 2.78bn | 346.64m | 8.23bn | 192.00 | 22.51 | 3.30 | 21.15 | 2.96 | 15.24 | 15.24 | 122.20 | 104.07 | 1.12 | 4.14 | 5.32 | 14,474,330.00 | 13.99 | -- | 15.95 | -- | 39.96 | -- | 12.47 | -- | 3.01 | 76.48 | 0.0046 | -- | 7.77 | -- | 9.60 | -- | -- | -- |
| Wanbury Ltd | 6.58bn | 646.86m | 8.78bn | 1.38k | 13.13 | -- | 11.09 | 1.33 | 19.13 | 19.13 | 194.16 | -- | -- | -- | -- | 4,758,967.00 | -- | 8.87 | -- | 101.40 | 55.07 | 41.82 | 9.84 | 5.62 | -- | 2.97 | -- | -- | 4.15 | 10.29 | -45.44 | -13.88 | 44.32 | -- |
| Venus Remedies Ltd | 7.00bn | 762.95m | 9.42bn | 1.30k | 12.34 | -- | 9.43 | 1.35 | 57.10 | 57.10 | 523.77 | -- | -- | -- | -- | 5,391,957.00 | -- | 6.67 | -- | 8.08 | 47.02 | 37.62 | 10.90 | 6.87 | -- | 1,849.19 | -- | -- | 7.72 | 13.81 | 59.05 | -- | 18.36 | -- |
| Bajaj Healthcare Ltd | 6.12bn | 523.16m | 10.14bn | 904.00 | 19.88 | -- | 12.71 | 1.65 | 16.15 | 15.36 | 188.83 | -- | -- | -- | -- | 6,774,850.00 | -- | 7.07 | -- | 13.07 | 46.31 | 37.17 | 8.54 | 8.22 | -- | 2.92 | -- | 5.83 | 14.61 | 5.76 | 399.64 | 11.21 | -12.65 | -- |
| Beta Drugs Ltd | -100.00bn | -100.00bn | 11.13bn | 399.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 15.08 | -- | 21.53 | -- | 40.30 | -- | 12.72 | -- | -- | -- | 0.00 | 22.54 | 31.89 | 28.96 | 37.92 | 19.23 | -- |
| Syncom Formulations (India) Ltd | 5.03bn | 689.58m | 11.27bn | 554.00 | 15.37 | -- | 15.17 | 2.24 | 0.78 | 0.78 | 5.58 | -- | -- | -- | -- | 9,072,854.00 | -- | 8.56 | -- | 11.58 | 40.05 | 34.81 | 13.72 | 10.15 | -- | 75.71 | -- | -- | 76.55 | 17.74 | 95.28 | 28.24 | 41.62 | -- |
| Jagsonpal Pharmaceuticals Ltd | 2.82bn | 409.03m | 11.59bn | 1.40k | 28.55 | -- | 23.04 | 4.12 | 6.07 | 6.07 | 41.76 | -- | -- | -- | -- | 2,012,738.00 | -- | 14.71 | -- | 17.26 | 63.66 | 60.59 | 14.53 | 12.54 | -- | 44.64 | -- | 39.88 | 28.76 | 11.13 | 146.45 | 47.72 | -28.44 | 65.72 |
| Sakar Healthcare Ltd | 2.31bn | 252.21m | 11.75bn | 342.00 | 46.10 | -- | 24.31 | 5.09 | 11.45 | 11.45 | 104.95 | -- | -- | -- | -- | 6,750,901.00 | -- | 4.73 | -- | 5.64 | 52.54 | 45.55 | 10.92 | 9.87 | -- | 3.66 | -- | -- | 15.80 | 16.44 | 49.96 | 12.71 | 19.34 | -- |
| IND Swift Laboratories Ltd | 9.64bn | 2.75bn | 11.87bn | 1.25k | 3.58 | -- | 3.69 | 1.23 | 38.28 | 38.28 | 122.91 | -- | -- | -- | -- | 7,738,014.00 | -- | 8.65 | -- | 10.59 | 51.55 | 40.96 | 28.56 | 14.35 | -- | -3.35 | -- | 0.00 | -56.15 | -6.35 | -40.50 | -- | 41.97 | -- |
| Lincoln Pharmaceuticals Ltd | 6.52bn | 878.34m | 12.35bn | 1.85k | 14.06 | -- | 12.13 | 1.89 | 43.86 | 43.86 | 325.55 | -- | -- | -- | -- | 3,518,272.00 | -- | 13.22 | -- | 15.46 | 53.64 | 50.82 | 13.47 | 14.56 | -- | 77.35 | -- | 3.32 | 7.35 | 10.03 | -11.74 | 9.87 | 20.13 | -- |
| Hester Biosciences Ltd | 3.14bn | 409.47m | 12.54bn | 562.00 | 39.12 | -- | 21.03 | 3.99 | 37.69 | 37.69 | 277.25 | -- | -- | -- | -- | 5,594,555.00 | -- | 5.39 | -- | 6.72 | 73.52 | 64.87 | 13.51 | 11.44 | -- | 9.65 | -- | 23.77 | 2.15 | 11.16 | 45.52 | -1.18 | -22.47 | 1.18 |
| Ngl Fine Chem Ltd | 4.47bn | 353.73m | 14.86bn | 456.00 | 42.00 | -- | 27.91 | 3.32 | 57.26 | 57.26 | 723.35 | -- | -- | -- | -- | 9,799,871.00 | -- | 13.34 | -- | 17.44 | 51.62 | 41.63 | 7.92 | 12.15 | -- | 9.06 | -- | 2.85 | 8.73 | 19.41 | -48.87 | 20.44 | 53.91 | 0.00 |
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 1.12m | 0.12% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 193.20k | 0.02% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Jan 2026 | 14.48k | 0.00% |
| Bandhan AMC Ltd.as of 31 Jan 2026 | 5.68k | 0.00% |
| DFA Australia Ltd.as of 30 Nov 2025 | 1.01k | 0.00% |
